pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Auryxia
drug
save

ferric citrate

Marketedupdated 3mo ago
by $AKBA Akebia Therapeutics, Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval2 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying ferric citrate

  • phase3Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Diseasesuspendedn=45
  • phase3Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Diseasewithdrawn
  • phase3Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Diseasecompletedn=289
  • phase3PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKDcompletedn=141
  • phase3Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysiscompletedn=239

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 21, 2030
~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

  • Jul 21, 2030method-of-use (U-2549)US 103000393.9y
  • Jul 21, 2030formulationUS 93871913.9y
  • Apr 21, 2026method-of-use (U-1577)US 8093423

News(0)

no news has mentioned this drug yet

brand
Auryxia
generic
ferric citrate
indication
Hyperphosphatemia In Chronic Kidney Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?